Analysts are skeptical of the massive 30-40% gap in 2026 sales projections between Eli Lilly (+25%) and Novo Nordisk (-5% to -13%). Given that the two companies are "joined at the hip" in the GLP-1 market, such a dramatic divergence in financial trajectory is considered highly improbable by some observers.
While Eli Lilly's Retrutide showed headline-grabbing weight loss, a concerning 18% of patients discontinued one study due to side effects. A subsequent trial showing a much lower discontinuation rate (5%) was seen as a major win, indicating patient tolerability is now as critical as raw efficacy for commercial success.
An HSBC analyst downgraded Eli Lilly, arguing its stock valuation assumes everything will go perfectly. This "priced to perfection" status means any small misstep, competitive pressure, or market shift could disproportionately impact its share price, creating significant downside risk despite the company's strong performance.
Lilly's Retrutide data highlights a key analytical nuance. The company reported weight loss using an "efficacy estimand" (assuming ideal patient adherence) but A1C data using a "treatment estimand" (accounting for missed doses). The latter provides a more realistic view of a drug's performance in the real world, where adherence is imperfect.
A significant portion of Eli Lilly's outperformance is driven by its Lilly Direct cash-pay channel, where customers pay out-of-pocket. An HSBC analyst warns this channel is more sensitive to changing economic conditions than insurance-based sales, making future revenue streams less predictable and potentially risky to forecast.